Table 5.
Associations between patients and treatment characteristics and stroke
| Covariate | N with stroke/N all patients | % at 20 years (95% CI) | Hazard ratio (95% CI) | p-value |
|---|---|---|---|---|
| Protocol | 0.002 | |||
| 58741 | 7/36 | 16.3 (7.5–35.4) | 1 | |
| 58831/2 | 4/172 | 1.8 (0.6–5.4) | 0.16 (0.04–0.59) | |
| 58881 | 12/583 | 2.2 (1.2–3.8) | 0.15 (0.05–0.45) | |
| Age at diagnosis, years | 0.033* | |||
| < 6 | 11/525 | 1.5 (0.7–3.1) | 1 | |
| 6–9 | 4/150 | 2.9 (1.1–7.7) | 1.15 (0.37–3.62)* | |
| 10–17 | 8/116 | 7.5 (3.8–14.8) | 3.35 (1.31–8.55)* | |
| CNS involvement at diagnosis** | ||||
| No CNS involvement | 20/743 | 2.5 (1.5–3.9) | ||
| CNS involvement | 2/41 | 5.4 (1.4–20.7) | ||
| VHR after consolidation** *** | ||||
| Not VHR | 9/524 | 1.8 (1.0–3.5) | ||
| VHR | 3/45 | 6.7 (2.2–19.9) | ||
| Randomized HD Cytarabine** *** | ||||
| No HD Cytarabine | 1/95 | 1.2 (0.2–8.4) | ||
| HD Cytarabine | 1/91 | 1.1 (0.2–7.7) | ||
CNS, central nervous system; HD Cytarabine, high-dose cytarabine; VHR, very high risk
*Adjusted for protocol
**A formal comparison using the Fine and Gray model was not performed due to the small number of events
***Based on the 58881 study only